Patents by Inventor Rudiger Pipkorn

Rudiger Pipkorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7563761
    Abstract: The invention relates to peptide nucleic acid (PNA) conjugates which can be used for treating diseases correlated with HIV, wherein the peptide nucleic acid (PNA) inhibits the gene expression of HIV. The conjugates comprise the following components: (a) a transport mediator for the cell membrane, (b) an address protein or peptide for the import into the cell nucleus, and (c) a peptide nucleic acid (PNA) which is to be transported and can be hybridized with an HIV gene and can inhibit the expression of the HIV gene.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: July 21, 2009
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Klaus Braun, Waldemar Waldeck, Rudiger Pipkorn, Isabell Braun, Jurgen Debus
  • Patent number: 7531502
    Abstract: Described is a diagnostic conjugate comprising (a) a transmembrane module (TPU), (b) an address module (AS), preferably an antisense peptide nucleic acid (PNA), and (c) a signaling module (SM). The conjugate is useful for intracellular imaging, preferably via MRI, and, e.g., for differentiating between tumor- and non-tumor cells.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: May 12, 2009
    Assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
    Inventors: Klaus Braun, Jürgen Debus, Jürgen Jenne, Rudiger Pipkorn, Ralf Rastert, Waldemar Waldeck, Isabell Braun, Stefan Heckl
  • Patent number: 7476658
    Abstract: The invention relates to a conjugate for treating prokaryotic infections from a transport mediator penetrating the prokaryotic cell membrane and a desired compound to be introduced into the prokaryote and directed thereagainst, which compound is preferably a peptide nucleic acid (PNA) directed against a gene of the prokaryote giving antibiotic resistance.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: January 13, 2009
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Klaus Braun, Isabell Braun, Jürgen Debus, Rudiger Pipkorn, Waldemar Waldeck
  • Publication number: 20060019249
    Abstract: Described is a diagnostic conjugate comprising (a) a transmembrane module (TPU), (b) an address module (AS), preferably an antisense peptide nucleic acid (PNA), and (c) a signalling module (SM). Said conjugate is useful for intracellular imaging, preferably via MRI, and, e.g., for differentiating between tumor- and non-tumor cells.
    Type: Application
    Filed: January 22, 2003
    Publication date: January 26, 2006
    Inventors: Klaus Braun, Jurgen Debus, Jurgen Jenne, Rudiger Pipkorn, Ralf Rastert, Waldemar Waldeck, Isabell Braun
  • Publication number: 20050250110
    Abstract: The invention relates to peptide nucleic acid (PNA) conjugates which inhibit the expression of the bcr/abl fusion gene characteristic of CML and are suited to treat chronic myeloid leukemia (CML).
    Type: Application
    Filed: May 6, 2004
    Publication date: November 10, 2005
    Inventors: Klaus Braun, Waldemar Waldeck, Rudiger Pipkorn, Isabell Braun, Jurgen Debus
  • Publication number: 20050222008
    Abstract: The invention relates to a conjugate for treating prokaryotic infections from a transport mediator penetrating the prokaryotic cell membrane and a desired compound to be introduced into the prokaryote and directed thereagainst, which compound is preferably a peptide nucleic acid (PNA) directed against a gene of the prokaryote giving antibiotic resistance.
    Type: Application
    Filed: January 17, 2003
    Publication date: October 6, 2005
    Inventors: Klaus Braun, Isabell Braun, Jurgen Debus, Rudiger Pipkorn, Waldemar Waldeck
  • Patent number: 6821948
    Abstract: The present invention relates to conjugates for mediating a cell-specific, compartment-specific or membrane-specific to methods of active substances. The invention also relates to methods of preparing these conjugates as well as their use. The conjugates comprise: a transport mediator for the cell membrane, a cell-specific, compartment-specific or membrane-specific address protein or peptide, and an active substance to be transported.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: November 23, 2004
    Assignee: Deutsche Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Klaus Braun, Peter Peschke, Eckart Friedrich, Rüdiger Pipkorn, Waldemar Waldeck, Jürgen Debus
  • Publication number: 20040220095
    Abstract: The invention relates to peptide nucleic acid (PNA) conjugates which can be used for treating diseases correlated with HIV, wherein the peptide nucleic acid (PNA) inhibits the gene expression of HIV. The conjugates comprise the following components: (a) a transport mediator for the cell membrane, (b) an address protein or peptide for the import into the cell nucleus, and (c) a peptide nucleic acid (PNA) which is to be transported and can be hybridized with an HIV gene and can inhibit the expression of the HIV gene.
    Type: Application
    Filed: April 21, 2004
    Publication date: November 4, 2004
    Inventors: Klaus Braun, Waldemar Waldeck, Rudiger Pipkorn, Isabell Braun, Jurgen Debus
  • Patent number: 6242174
    Abstract: A method of discriminating between specific antibodies in samples of sera or other body fluids from humans or other primates containing antibodies arising from infection with HTLV-I, containing antibodies arising from infection with HTLV-II or containing antibodies arising from infection with related retroviruses, is described. In said method, the sample to be analyzed is subjected to at least four immunoassays, each using a different diagnostic antigen selected from four defined groups of peptides. Additionally, an immunoassay kit adapted for said method of discrimination, new peptides and a method of detecting antibodies with said peptides, are described.
    Type: Grant
    Filed: October 7, 1991
    Date of Patent: June 5, 2001
    Assignee: Replico Medical AB
    Inventors: Jonas Blomberg, Rüdiger Pipkorn